

## PATENT ASSIGNMENT COVER SHEET

Electronic Version v1.1  
Stylesheet Version v1.2

EPAS ID: PAT7573254

<b>SUBMISSION TYPE:</b>	NEW ASSIGNMENT
<b>NATURE OF CONVEYANCE:</b>	ASSIGNMENT
<b>CONVEYING PARTY DATA</b>	
<b>Name</b>	<b>Execution Date</b>
ANDREI W. KONRADI	11/13/2015
STEPHEN S. DOMINY	10/14/2015
CASEY CRAWFORD LYNCH	11/13/2015
CRAIG COBURN	10/06/2015
JOSEPH VACCA	10/07/2015
<b>RECEIVING PARTY DATA</b>	
<b>Name:</b>	CORTEXYME, INC.
<b>Street Address:</b>	269 EAST GRAND AVENUE
<b>City:</b>	SOUTH SAN FRANCISCO
<b>State/Country:</b>	CALIFORNIA
<b>Postal Code:</b>	94080
<b>PROPERTY NUMBERS Total: 2</b>	
<b>Property Type</b>	<b>Number</b>
<b>Application Number:</b>	16866022
<b>Application Number:</b>	17744513
<b>CORRESPONDENCE DATA</b>	
<b>Fax Number:</b>	(925)472-8895
<i>Correspondence will be sent to the e-mail address first; if that is unsuccessful, it will be sent using a fax number, if provided; if that is unsuccessful, it will be sent via US Mail.</i>	
<b>Phone:</b>	9254725000
<b>Email:</b>	jluna@kilpatricktownsend.com
<b>Correspondent Name:</b>	EUGENIA GARRETT-WACKOWSKI
<b>Address Line 1:</b>	KILPATRICK TOWNSEND & STOCKTON LLP
<b>Address Line 2:</b>	TWO EMBARCADERO CENTER, SUITE 1900
<b>Address Line 4:</b>	SAN FRANCISCO, CALIFORNIA 94111-3734
<b>ATTORNEY DOCKET NUMBER:</b>	098460-000360US-1329207
<b>NAME OF SUBMITTER:</b>	JOSE LUNA
<b>SIGNATURE:</b>	/Jose Luna/
<b>DATE SIGNED:</b>	10/04/2022

**Total Attachments: 12**

source=350US&360US\_Assignment1\_Inventors-Cortexyme#page1.tif

source=350US&360US\_Assignment1\_Inventors-Cortexyme#page2.tif

source=350US&360US\_Assignment1\_Inventors-Cortexyme#page3.tif

source=350US&360US\_Assignment1\_Inventors-Cortexyme#page4.tif

source=350US&360US\_Assignment1\_Inventors-Cortexyme#page5.tif

source=350US&360US\_Assignment1\_Inventors-Cortexyme#page6.tif

source=350US&360US\_Assignment1\_Inventors-Cortexyme#page7.tif

source=350US&360US\_Assignment1\_Inventors-Cortexyme#page8.tif

source=350US&360US\_Assignment1\_Inventors-Cortexyme#page9.tif

source=350US&360US\_Assignment1\_Inventors-Cortexyme#page10.tif

source=350US&360US\_Assignment1\_Inventors-Cortexyme#page11.tif

source=350US&360US\_Assignment1\_Inventors-Cortexyme#page12.tif

**ASSIGNMENT**  
(Patent Application)

We, the undersigned, have invented certain inventions and improvements disclosed in a nonprovisional patent application entitled

“INHIBITORS OF LYSINE GINGIPAIN,”

filed with the U.S. Patent & Trademark Office on October 5, 2015

and assigned serial no. 14/875,416.

For good and valuable consideration, the receipt and sufficiency of which we acknowledge, we:

1. Agree to assign, transfer, and convey, hereby assign, transfer, and convey, and have assigned, transferred, and conveyed to Cortexyme, Inc., a corporation of the State of Delaware having a principal place of business at J&J Innovation, J Labs, 329 Oyster Point, Suite 300, South San Francisco, CA 94080 (“Assignee”), the entire right, title, and interest in and to:
  - (a) all intellectual property (including, without limitation, any innovation, information, invention, discovery, product, process, work or design) disclosed, embodied, shown, or claimed in the above-referenced patent application, implicitly or explicitly;
  - (b) the above-referenced patent application, the right to claim priority to the above-referenced patent application, all applications based in whole or in part upon the above-referenced patent application, including, without limitation, all applications that are a provisional, non-provisional, design, divisional, continuation, continuation-in-part, registration, utility model, industrial design, reissue, renewal, substitute, extension, reexamination, post-grant review, inter partes review, supplemental examination or non-U.S. patent application or application for other rights based in whole or in part on the above-referenced patent application;
  - (c) all patents (including, without limitation, all U.S. and non-U.S. patents, registrations, utility models, industrial designs, design patents, counterparts, continuations, continuations-in-part, divisionals, reissues, renewals, substitutes, extensions, reexaminations, post-grant reviews, inter partes reviews and supplemental examinations) that are granted or issued upon, or that claim priority to, any and all applications described in (b) of this paragraph or that disclose or claim intellectual property described in (a) of this paragraph, in whole or in part; and

ASSIGNMENT

U.S. Serial No. 14/875,416

Attorney Docket No. 098460-000310US-0958907

Page 2 of 3

- (d) all claims for damages by reason of past infringement of any rights under the applications or patents described in (a), (b) or (c) of this paragraph (including provisional rights to reasonable royalties pursuant to 35 U.S.C. §154(d)) and the right to sue for and collect such damages and royalties for Assignee's own use.
2. Authorize and request the U.S. Patent and Trademark Office or any other U.S. or non-U.S. agency to issue to the Assignee any and all patent(s), or other rights or documents, resulting from the intellectual property, patent application(s) and patents described in paragraph 1 of this Assignment.
  3. Agree to sign all papers and documents, including without limitation, applications, declarations, oaths and petitions, and, at the Assignee's expense, perform any other acts that are necessary in connection with prosecution of patent application(s) or intellectual property described in paragraph 1 of this Assignment and the enforcement of patent(s) or other rights resulting from such patent application(s) or intellectual property.
  4. Agree that the terms, covenants, and conditions of this Assignment shall inure to the benefit of the Assignee, its successors, assigns and other legal representative, and shall be binding upon us, as well as our heirs, legal representatives, and assigns.
  5. Promise and affirm that we have not entered, and will not enter, into any assignment, contract, or understanding that conflicts with this Assignment.

Signed on the dates indicated beside our signatures.

Signature: Andrei W. Konradi Date: November 13, 2015  
Andrei Konradi


Signature: \_\_\_\_\_ Date: \_\_\_\_\_  
Stephen S. Dominy

ASSIGNMENT

U.S. Serial No. 14/875,416

Attorney Docket No. 098460-000310US-0958907

Page 3 of 3

Signature:   
Casey Crawford Lynch

Date: 11/13/2015

Signature: \_\_\_\_\_  
Craig Coburn

Date: \_\_\_\_\_

Signature: \_\_\_\_\_  
Joseph Vacca

Date: \_\_\_\_\_

Assignee hereby accepts this Assignment:

Date: \_\_\_\_\_

67787338V.1

**ASSIGNMENT**  
(Patent Application)

We, the undersigned, have invented certain inventions and improvements disclosed in a nonprovisional patent application entitled

“INHIBITORS OF LYSINE GINGIPAIN,”

filed with the U.S. Patent & Trademark Office on October 5, 2015

and assigned serial no. 14/875,416.

For good and valuable consideration, the receipt and sufficiency of which we acknowledge, we:

1. Agree to assign, transfer, and convey, hereby assign, transfer, and convey, and have assigned, transferred, and conveyed to Cortexyme, Inc., a corporation of the State of Delaware having a principal place of business at J&J Innovation, J Labs, 329 Oyster Point, Suite 300, South San Francisco, CA 94080 (“Assignee”), the entire right, title, and interest in and to:
  - (a) all intellectual property (including, without limitation, any innovation, information, invention, discovery, product, process, work or design) disclosed, embodied, shown, or claimed in the above-referenced patent application, implicitly or explicitly;
  - (b) the above-referenced patent application, the right to claim priority to the above-referenced patent application, all applications based in whole or in part upon the above-referenced patent application, including, without limitation, all applications that are a provisional, non-provisional, design, divisional, continuation, continuation-in-part, registration, utility model, industrial design, reissue, renewal, substitute, extension, reexamination, post-grant review, inter partes review, supplemental examination or non-U.S. patent application or application for other rights based in whole or in part on the above-referenced patent application;
  - (c) all patents (including, without limitation, all U.S. and non-U.S. patents, registrations, utility models, industrial designs, design patents, counterparts, continuations, continuations-in-part, divisionals, reissues, renewals, substitutes, extensions, reexaminations, post-grant reviews, inter partes reviews and supplemental examinations) that are granted or issued upon, or that claim priority to, any and all applications described in (b) of this paragraph or that disclose or claim intellectual property described in (a) of this paragraph, in whole or in part; and


(d) all claims for damages by reason of past infringement of any rights under the applications or patents described in (a), (b) or (c) of this paragraph (including provisional rights to reasonable royalties pursuant to 35 U.S.C. §154(d)) and the right to sue for and collect such damages and royalties for Assignee's own use.

2. Authorize and request the U.S. Patent and Trademark Office or any other U.S. or non-U.S. agency to issue to the Assignee any and all patent(s), or other rights or documents, resulting from the intellectual property, patent application(s) and patents described in paragraph 1 of this Assignment.
3. Agree to sign all papers and documents, including without limitation, applications, declarations, oaths and petitions, and, at the Assignee's expense, perform any other acts that are necessary in connection with prosecution of patent application(s) or intellectual property described in paragraph 1 of this Assignment and the enforcement of patent(s) or other rights resulting from such patent application(s) or intellectual property.
4. Agree that the terms, covenants, and conditions of this Assignment shall inure to the benefit of the Assignee, its successors, assigns and other legal representative, and shall be binding upon us, as well as our heirs, legal representatives, and assigns.
5. Promise and affirm that we have not entered, and will not enter, into any assignment, contract, or understanding that conflicts with this Assignment.

Signed on the dates indicated beside our signatures.

Signature: \_\_\_\_\_ Date: \_

Andrei Konradi

Signature:  \_\_\_\_\_ Date: 10-14-15

Stephen S. Dominy

ASSIGNMENT

U.S. Serial No. 14/875,416

Attorney Docket No. 098460-000310US-0958907

Page 3 of 3

Signature: \_\_\_\_\_

Casey Crawford Lynch

Date: \_\_\_\_\_

Signature: \_\_\_\_\_

Craig Coburn

Date: \_\_\_\_\_

Signature: \_\_\_\_\_

Joseph Vacca

Date: \_\_\_\_\_

Assignee hereby accepts this Assignment:

Date: \_\_\_\_\_

67787338V.1



**ASSIGNMENT**  
(Patent Application)

We, the undersigned, have invented certain inventions and improvements disclosed in a nonprovisional patent application entitled

“INHIBITORS OF LYSINE GINGIPAIN,”

filed with the U.S. Patent & Trademark Office on October 5, 2015

and assigned serial no. 14/875,416.

For good and valuable consideration, the receipt and sufficiency of which we acknowledge, we:

1. Agree to assign, transfer, and convey, hereby assign, transfer, and convey, and have assigned, transferred, and conveyed to Cortexyme, Inc., a corporation of the State of Delaware having a principal place of business at J&J Innovation, J Labs, 329 Oyster Point, Suite 300, South San Francisco, CA 94080 (“Assignee”), the entire right, title, and interest in and to:
  - (a) all intellectual property (including, without limitation, any innovation, information, invention, discovery, product, process, work or design) disclosed, embodied, shown, or claimed in the above-referenced patent application, implicitly or explicitly;
  - (b) the above-referenced patent application, the right to claim priority to the above-referenced patent application, all applications based in whole or in part upon the above-referenced patent application, including, without limitation, all applications that are a provisional, non-provisional, design, divisional, continuation, continuation-in-part, registration, utility model, industrial design, reissue, renewal, substitute, extension, reexamination, post-grant review, inter partes review, supplemental examination or non-U.S. patent application or application for other rights based in whole or in part on the above-referenced patent application;
  - (c) all patents (including, without limitation, all U.S. and non-U.S. patents, registrations, utility models, industrial designs, design patents, counterparts, continuations, continuations-in-part, divisionals, reissues, renewals, substitutes, extensions, reexaminations, post-grant reviews, inter partes reviews and supplemental examinations) that are granted or issued upon, or that claim priority to, any and all applications described in (b) of this paragraph or that disclose or claim intellectual property described in (a) of this paragraph, in whole or in part; and

ASSIGNMENT

U.S. Serial No. 14/875,416

Attorney Docket No. 098460-000310US-0958907

Page 2 of 3

- (d) all claims for damages by reason of past infringement of any rights under the applications or patents described in (a), (b) or (c) of this paragraph (including provisional rights to reasonable royalties pursuant to 35 U.S.C. §154(d)) and the right to sue for and collect such damages and royalties for Assignee's own use.
2. Authorize and request the U.S. Patent and Trademark Office or any other U.S. or non-U.S. agency to issue to the Assignee any and all patent(s), or other rights or documents, resulting from the intellectual property, patent application(s) and patents described in paragraph 1 of this Assignment.
  3. Agree to sign all papers and documents, including without limitation, applications, declarations, oaths and petitions, and, at the Assignee's expense, perform any other acts that are necessary in connection with prosecution of patent application(s) or intellectual property described in paragraph 1 of this Assignment and the enforcement of patent(s) or other rights resulting from such patent application(s) or intellectual property.
  4. Agree that the terms, covenants, and conditions of this Assignment shall inure to the benefit of the Assignee, its successors, assigns and other legal representative, and shall be binding upon us, as well as our heirs, legal representatives, and assigns.
  5. Promise and affirm that we have not entered, and will not enter, into any assignment, contract, or understanding that conflicts with this Assignment.

Signed on the dates indicated beside our signatures.

Signature: \_\_\_\_\_

Andrei Konradi

Date: \_\_\_\_\_

Signature: \_\_\_\_\_

Stephen S. Dominy


Date: \_\_\_\_\_

ASSIGNMENT  
U.S. Serial No. 14/875,416  
Attorney Docket No. 098460-000310US-0958907  
Page 3 of 3

Signature: \_\_\_\_\_

Casey Crawford Lynch

Date: \_\_\_\_\_

Signature:  \_\_\_\_\_

Craig Coburn

Date: 6 OCT 2015

Signature: \_\_\_\_\_

Joseph Vacca

Date: \_\_\_\_\_

Assignee hereby accepts this Assignment:

Date: \_\_\_\_\_

67787338V.1

**ASSIGNMENT**  
(Patent Application)

We, the undersigned, have invented certain inventions and improvements disclosed in a nonprovisional patent application entitled

“INHIBITORS OF LYSINE GINGIPAIN,”

filed with the U.S. Patent & Trademark Office on October 5, 2015

and assigned serial no. 14/875,416.

For good and valuable consideration, the receipt and sufficiency of which we acknowledge, we:

1. Agree to assign, transfer, and convey, hereby assign, transfer, and convey, and have assigned, transferred, and conveyed to Cortexyme, Inc., a corporation of the State of Delaware having a principal place of business at J&J Innovation, J Labs, 329 Oyster Point, Suite 300, South San Francisco, CA 94080 (“Assignee”), the entire right, title, and interest in and to:
  - (a) all intellectual property (including, without limitation, any innovation, information, invention, discovery, product, process, work or design) disclosed, embodied, shown, or claimed in the above-referenced patent application, implicitly or explicitly;
  - (b) the above-referenced patent application, the right to claim priority to the above-referenced patent application, all applications based in whole or in part upon the above-referenced patent application, including, without limitation, all applications that are a provisional, non-provisional, design, divisional, continuation, continuation-in-part, registration, utility model, industrial design, reissue, renewal, substitute, extension, reexamination, post-grant review, inter partes review, supplemental examination or non-U.S. patent application or application for other rights based in whole or in part on the above-referenced patent application;
  - (c) all patents (including, without limitation, all U.S. and non-U.S. patents, registrations, utility models, industrial designs, design patents, counterparts, continuations, continuations-in-part, divisionals, reissues, renewals, substitutes, extensions, reexaminations, post-grant reviews, inter partes reviews and supplemental examinations) that are granted or issued upon, or that claim priority to, any and all applications described in (b) of this paragraph or that disclose or claim intellectual property described in (a) of this paragraph, in whole or in part; and

ASSIGNMENT

U.S. Serial No. 14/875,416

Attorney Docket No. 098460-000310US-0958907

Page 2 of 2

- (d) all claims for damages by reason of past infringement of any rights under the applications or patents described in (a), (b) or (c) of this paragraph (including provisional rights to reasonable royalties pursuant to 35 U.S.C. §154(d)) and the right to sue for and collect such damages and royalties for Assignee's own use.
2. Authorize and request the U.S. Patent and Trademark Office or any other U.S. or non-U.S. agency to issue to the Assignee any and all patent(s), or other rights or documents, resulting from the intellectual property, patent application(s) and patents described in paragraph 1 of this Assignment.
  3. Agree to sign all papers and documents, including without limitation, applications, declarations, oaths and petitions, and, at the Assignee's expense, perform any other acts that are necessary in connection with prosecution of patent application(s) or intellectual property described in paragraph 1 of this Assignment and the enforcement of patent(s) or other rights resulting from such patent application(s) or intellectual property.
  4. Agree that the terms, covenants, and conditions of this Assignment shall inure to the benefit of the Assignee, its successors, assigns and other legal representative, and shall be binding upon us, as well as our heirs, legal representatives, and assigns.
  5. Promise and affirm that we have not entered, and will not enter, into any assignment, contract, or understanding that conflicts with this Assignment.

Signed on the dates indicated beside our signatures.

Signature: \_\_\_\_\_

Andrei Konradi

Date: \_\_\_\_\_

Signature: \_\_\_\_\_

Stephen S. Dominy

Date: \_\_\_\_\_

ASSIGNMENT

U.S. Serial No. 14/875,416

Attorney Docket No. 098460-000310US-0958907

Page 3 of 2

Signature: \_\_\_\_\_  
Casey Crawford Lynch

Date:

Signature: \_\_\_\_\_  
Craig Coburn

Date: \_\_\_\_\_

Signature: Joseph Vacca  
Joseph Vacca

Date: Oct 7, 2015

Assignee hereby accepts this Assignment:

Date: \_\_\_\_\_

67787338V.1